RVNC - Revance Therapeutics stock slides on pricing $200.0M upsized stock offering
- Revance Therapeutics ( NASDAQ: RVNC ) stock is down 5.9% after-hours after the firm has priced an upsized underwritten public offering of 8M shares of its common stock at a public offering price of $25.00/share for expected gross proceeds to be $200.0M.
- All of the shares are being offered by Revance.
- Underwriters are granted a 30-day option to purchase up to an additional 1.2M shares of its common stock at the public offering price.
- Offering is expected to close on or about September 15, 2022.
- Net proceeds from the offering will be used to fund the commercialization of DAXXIFY™, the RHA® Collection of dermal fillers and OPUL®, and for working capital, research and development and general corporate purposes.
- Earlier, Revance Therapeutics plans underwritten public offering of $150M shares .
For further details see:
Revance Therapeutics stock slides on pricing $200.0M upsized stock offering